TLR2 and cancer: This is a consequence of the dedifferentiation of CD133− cancer cells into CD133+ CSCs mediated by TLR2 activation of the Hippo-Yes-associated protein (YAP) signaling pathway, suggesting that chemotherapy- and radiation-induced cancer cell death establishes a supporting niche for cancer cell stemness [96].